Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$71,871 Mln
P/E Ratio
21.57
P/B Ratio
4.04
Industry P/E
--
Debt to Equity
1.24
ROE
0.23 %
ROCE
8.3 %
Div. Yield
4.4 %
Book Value
3.3
EPS
0.62
CFO
£67,745.00 Mln
EBITDA
£82,554.00 Mln
Net Profit
£41,873.00 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
GlaxoSmithKline - ADR
| 6.24 | -9.01 | 7.45 | -10.06 | -1.61 | 1.09 | -0.75 |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
GlaxoSmithKline - ADR
| -8.67 | 5.46 | -20.32 | 19.84 | -21.69 | 22.98 | 7.68 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates... through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, infectious, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, inflammation, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop vaccines for influenza and COVID-19, as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in London, United Kingdom. Address: 79 New Oxford Street, London, United Kingdom, WC1A 1DG Read more
CEO & Director
Ms. Emma Natasha Walmsley
CEO & Director
Ms. Emma Natasha Walmsley
Headquarters
England
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of GlaxoSmithKline PLC - ADR stood at $ 59,463 Mln as on 31-Dec-24
The share price of GlaxoSmithKline PLC - ADR is $35.93 (NYSE) as of 17-Apr-2025 16:10 EDT. GlaxoSmithKline PLC - ADR has given a return of -1.61% in the last 3 years.
GlaxoSmithKline PLC - ADR has a market capitalisation of $ 71,871 Mln as on 17-Apr-2025. As per Value Research classification, it is a company.
The P/E ratio of GlaxoSmithKline PLC - ADR is 21.57 times as on 17-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the GlaxoSmithKline PLC - ADR and enter the required number of quantities and click on buy to purchase the shares of GlaxoSmithKline PLC - ADR.
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, infectious, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, inflammation, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop vaccines for influenza and COVID-19, as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in London, United Kingdom. Address: 79 New Oxford Street, London, United Kingdom, WC1A 1DG
The CEO & director of Ms. Emma Natasha Walmsley. is GlaxoSmithKline PLC - ADR, and CFO & Sr. VP is Ms. Emma Natasha Walmsley.
There is no promoter pledging in GlaxoSmithKline PLC - ADR.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| GlaxoSmithKline PLC - ADR | Ratios |
|---|---|
|
Return on equity(%)
|
19.06
|
|
Operating margin(%)
|
13.12
|
|
Net Margin(%)
|
8.21
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of GlaxoSmithKline PLC - ADR was $0 Mln.
$0.56
(
